Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

199.65
+7.013.64%
Post-market: 199.650.00000.00%19:28 EDT
Volume:196.17K
Turnover:38.96M
Market Cap:3.98B
PE:32.57
High:201.96
Open:195.98
Low:192.96
Close:192.64
52wk High:227.92
52wk Low:93.58
Shares:19.94M
Float Shares:19.46M
Volume Ratio:0.93
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.13
EPS(LYR):6.13
ROE:13.47%
ROA:2.36%
PB:3.91
PE(LYR):32.57

Loading ...

Ligand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case

Simply Wall St.
·
Feb 28

Xintong Pharmaceutical's IPO: Unstable Revenue, Halved R&D, Reduced Fundraising Targets Amid Intense Competition Clouding Commercial Prospects

Deep News
·
Feb 28

BRIEF-Ligand Pharmaceuticals Files For Mixed Shelf Offering

Reuters
·
Feb 28

Ligand files automatic mixed securities shelf

TIPRANKS
·
Feb 28

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M

MT Newswires Live
·
Feb 26

Ligand’s FY 2025 royalty revenue rises 48% to USD 161.0 million

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Adj. EPS $2.02 Beats $1.56 Estimate, Sales $59.666M Beat $55.589M Estimate.

Benzinga
·
Feb 26

BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Pretax Profit USD 56.78 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Reiterates FY Guidance of $245-$285 Mln in Revenues & Adj EPS of $8.00-$9.00

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Expects 2026 Royalty Revenue to Be in Range of $200 Million to $225 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Q4 Basic EPS USD 2.27

THOMSON REUTERS
·
Feb 26

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Ligand price target raised to $239 from $231 at H.C. Wainwright

TIPRANKS
·
Feb 25

Earning Preview: Ligand Pharmaceuticals this quarter’s revenue is expected to increase by 42.45%, and institutional views are limited

Earnings Agent
·
Feb 19

Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 16

Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Share Price Weakness And Strong 1 Year Return

Simply Wall St.
·
Feb 15

Has Ligand Pharmaceuticals (LGND) Run Too Far After Its 59% One-Year Share Price Surge?

Simply Wall St.
·
Feb 13